Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD(A, B)
Kalyna Z. Bezchlibnyk-Butler, BScPhm, FCSHP
J. Joel Jeffries, MB, FRCPC,
DFCPA(C)
The Editors wish to acknowledge contributions from the following chapter
co-editors:
Alasdair M. Barr, PhD(D) (Drugs of Abuse)
Agnieszka K. Biala, MPharm, PhD(E) (Sex-Drive Depressants)
Andrius Baskys, MD, PhD(F) (Drugs for Treatment of Dementia, Pharmacogenetic Information for Common Psychotropic Drugs)
Vincent Dagenais-Beaulé, MSc, PharmD(G) (Antipsychotics)
Lynda Eccott, BSc, MScPharm(H) (Natural Health Products)
Dean Elbe, BScPharm, PharmD, BCPP(I) (Drugs for ADHD)
Katelyn Halpape, BSP, ACPR, PharmD, BCPP(J) (Mood Stabilizers)
Gary Hasey, MD, FRCPC, MSc(K) (Repetitive Transcranial Magnetic Stimulation)
David D. Kim, MSc(D) (Antipsychotic-Induced Extrapyramidal Side Effects and Their Management, Drugs of Abuse)
Melanie McLeod, BSP, ACPR, PharmD, BCPP(L) (Mood Stabilizers)
Reza Rafizadeh, BScPharm, RPh, ACPR, BCPP(M) (Antipsychotics, Treatment of Substance Use Disorders)
Christian G. Schütz, MD, PhD, MPH, FRCPC(N) (Treatment of Substance Use Disorders)
Jacky T. P. Siu, BScPharm, ACPR, PharmD, BCPP(M) (Anxiolytics, Hypnotics/Sedatives)
Fidel Vila-Rodriguez, MD, PhD, FRCPC, FAPA(A) (Electroconvulsive Therapy)
Vivian Yih, BScPharm, PharmD(O) (Antidepressants)
Bree Zehm, PharmD(P) (Antidepressants)
Tony Zhou, PharmD, ACPR(C, Q) (Antidepressants, Antipsychotics, Drug Interactions)
(A) Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
(B) British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada
(C) Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada
(D) Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada
(E) Department of Pediatrics, Canadian Pharmacogenomics Network for Drug Safety, University of British Columbia, Vancouver, BC, Canada
(F) Riverside Psychiatric Medical Group Memory Disorders Program, Riverside, CA, USA
(G) Department of Clinical Pharmacy, Jewish General Hospital, Lady Davis Institute for Medical Research & Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada
(H) Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(I) Healthy Minds Centre, BC Children's Hospital, Vancouver, BC, Canada
(J) College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada
(K) Departments of Psychiatry and Behavioural Neurosciences, Biomedical, Electrical and Computer Engineering, McMaster University, Hamilton, ON, Canada
(L) Department of Psychiatry, Saskatchewan Health Authority, Regina, SK, Canada
(M) Lower Mainland Pharmacy Services and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(N) Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada, and Burnaby Center for Mental Health & Addiction, Burnaby, BC, Canada
(O) Fraser Health Authority Mental Health and Substance Use Tertiary Older Adult Program, Vancouver, BC, Canada
(P) Department of Pharmacy, Island Health, Victoria, BC, Canada
(Q) Lower Mainland Pharmacy Services and Surrey Memorial Hospital, Surrey, BC, Canada